One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth, interview-led coverage explores the decisive factors behind the CRL, lessons learned, and the future of psychedelic drug development.
